Bangalore August 10, 2009
Syngene International, a subsidiary of BIOCON Ltd, Indian biotechnology major, announced today that it has been officially accredited by The AAALAC International (the Association for Assessment and Accreditation of Laboratory Animal Care International). The AAALAC International accreditation program evaluates organizations that use animals in research, teaching or testing. Those that meet or exceed AAALAC standards are awarded accreditation.
Goutam Das, COO Syngene, said, "Accreditation benefits an institution and the animals in its care in many ways. Each time a new organization becomes accredited, it helps to raise the global benchmark for animal well-being in science. We are delighted to receive this accreditation, as it only confirms our quality norms and the global standards we follow."
After an institution earns accreditation, it must be re-evaluated every three years in order to maintain its accredited status. Currently more than 770 organizations in 31 countries have earned AAALAC accreditation.
About Syngene International Limited
Established in 1994, Syngene is among India's foremost integrated custom research and manufacturing service providers with multidisciplinary skills in Chemistry, Biology, Pre-clinical, Biologics and Oral formulation development services to support discovery and development programs of leading players in the global pharmaceutical and biotechnology industries. Located in a Special Economic Zone at Bangalore with a 1200 plus skilled talent pool of scientists, Syngene a "full-service research hub is equipped to partner with clients right from early stage discovery and development to cGMP manufacture of complex development compounds for both small and large molecules in the most efficient manner in terms of cost, quality and time".
Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Together with its group companies. Biocon forms a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research and clinical research which deliver products and solutions to partners and customers across the globe. Biocon launched the world's first recombinant human insulin, INSUGEN® in November 2004 using Pichia expression and India's first indigenously produced monoclonal antibody BIOMAb-EGFR™.
Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, Biocon offers novel therapies on a platform of affordable innovation. Biocon’s strategic licensing partnerships provide market penetration and global access to deliver breakthrough therapeutics to millions of patients the world over.